Clinical trials: Apixaban
Anticoagulants; Increased
Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis
Direct Oral Anticoagulants INTRODUCTION: DOAC's looks like an attractive alternative to VKA because they offer important advantages beyond their easiness of administration, like less interactions and no need of laboratory…
- Trial name
- NCT05705076
- Testing
- catheter induced thromboprophylaxis
- Volunteers
- 1,100 people
- Sponsor
- Mansoura University
Venous Thromboembolism, Pharmacokinetics
Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus
This study aims to evaluate the pharmacokinetics (PK) of apixaban when co-administered with cyclosporine and tacrolimus in healthy volunteers.
- Conditions
- Venous Thromboembolism, Pharmacokinetics, Healthy
- Trial name
- ACT (NCT03083782)
- Testing
- Apixaban alone, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Unsuspected Pulmonary Embolism
Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
The same initial and long-term anticoagulation is suggested for unsuspected pulmonary embolism as for patients with symptomatic embolism.
- Trial name
- NCT01727427
- Testing
- Heparin, fondaparinux, vitamin-K antagonists, aspirin
- Where
- 46 sites in United States, Austria and 6 more
- Volunteers
- 695 people
- Sponsor
- G. d'Annunzio University
Atrial Fibrillation
Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
Study objective is to demonstrate that anticoagulation with the direct factor Xa inhibitor apixaban is not less safe than Vitamin-K-antagonists (VKA) therapy in patients undergoing catheter ablation of non-valvular AF in the…
- Trial name
- AXAFA (NCT02227550)
- Testing
- Vitamin K antagonist, Apixaban
- Where
- 13 sites in United States, Austria and 7 more
- Volunteers
- 676 people
- Sponsor
- Atrial Fibrillation Network
Left Atrial Appendage Closure, Thrombosis
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
The objective of the study is to compare short-term (8 weeks) anticoagulation therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter LAAC.
- Conditions
- Left Atrial Appendage Closure, Thrombosis, Stroke, TIA
- Trial name
- ANDES (NCT03568890)
- Testing
- Rivaroxaban, dabigatran, apixaban, or edoxaban, Clopidogrel -75 mg/day, Low dose aspirin -80 to 125 mg/day-
- Where
- Canada
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Atrial Fibrillation
Left Atrial Appendage Occlusion Versus New Oral Anticoagulants for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation
We will compare long-term effectiveness and safety in patients with atrial fibrillation treated with left atrial appendage occlusion versus new oral anticoagulants to prevent ischemic stroke from multicenter registry data
- Trial name
- NCT03108872
- Testing
- left atrial appendage occlusion, New oral anticoagulants
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Sejong General Hospital
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 1
The investigators study aims to test the correlation between the CoaguChek point-of-care testing (POCT) device (Roche, Switzerland) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC…
- Trial name
- POCT-DOAC 1 (NCT02371044)
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Left Atrial Appendage Occlusion
Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)
Objective: To demonstrate superiority of a strategy of anticoagulation with apixaban 5mg/2.5mg bid as compared with the current standard of care (dual antiplatelet therapy) after occlusion of the left atrial appendage (LAAC) in…
- Trial name
- ADALA (NCT05632445)
- Testing
- Apixaban vs. DAPT
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- DR. XAVIER FREIXA
Atrial Fibrillation
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
This population-based study will identify patients with rapid and irregular heartbeat which is not due to a fault with the heart valves (non-valvular atrial fibrillation) who initiate rivaroxaban, apixaban or warfarin as…
- Trial name
- SiERRA UK (NCT03847181)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Warfarin
- Where
- United Kingdom
- Volunteers
- 45,164 people
- Sponsor
- Bayer
COVID-19
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
The purpose of the study is to describe the safety and efficacy outcomes of a cohort of ICU patients with severe COVID-19 respiratory disease treated with therapeutic dose Apixaban for COVID-19 at a tertiary public health care…
- Trial name
- ECRU (NCT05088928)
- Testing
- Apixaban, Rivaroxaban
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Scotmann Pharmaceuticals
Healthy
Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects
To evaluate the single-center, open, randomized, single-dose, two-cycle, two-sequence, cross-over bioequivalence of test preparation apixaban tablet 2.5mg and reference preparation 2.5mg in healthy adult subjects in fasting and…
- Trial name
- NCT05841446
- Testing
- test apixaban tablets, reference apixaban tablets
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban.
- Trial name
- ROXI-EVEREST (NCT07626411)
- Testing
- REGN7508, Apixaban
- Where
- 54 sites in United States, Canada and 1 more
- Volunteers
- 15,364 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Atrial Fibrillation
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial fibrillation (AF) is the most common sustained abnormal rhythm of the heart, affects an estimated 2.5 to 5 million individuals in the US, and can lead to stroke, heart failure, and premature death.
- Trial name
- REACT COM (NCT01706146)
- Testing
- Non-coumadin Oral Anticoagulant
- Where
- 3 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Northwestern University
Venous Thromboembolism, Pulmonary Embolism
Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, DVT
- Trial name
- NCT05264168
- Testing
- Rivaroxaban, Apixaban
- Where
- United States
- Volunteers
- 41,875 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
The primary purpose of this study is to evaluate comparative effectiveness and safety outcomes of therapies to prevent thromboembolic events in patients with nonvalvular atrial fibrillation by using Korean nationwide health…
- Trial name
- NCT03572972
- Testing
- Apixaban, Dabigatran, Rivaroxaban
- Where
- South Korea
- Volunteers
- 64,684 people
- Sponsor
- Pfizer
Atrial Fibrillation (AF)
Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)
Patients taking Factor Xa inhibitors (Apixaban, Rivaroxaban) in atrial fibrillation will be conducted a follow-up investigation on systemic embolism and bleeding events.
- Trial name
- NCT06779695
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Korea University Anam Hospital
Atrial Fibrillation, Left Atrial Appendage Thrombosis
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF
The primary objective is to demonstrate the safety and efficacy of the implantation of the LAmbre PlusTM device in patients with large or irregularly shaped appendages with non-valvular atrial fibrillation who are at increased…
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
- Trial name
- CORRAL-AF (NCT04684212)
- Testing
- LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
- Where
- United States
- Sponsor
- Brian O'Neill MD
Atrial Fibrillation
Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study
This study is being done to determine if apixaban is more safe, when compared to warfarin, at reducing the risk of bleeding during CIED procedures.
- Trial name
- Apixaban (NCT02450682)
- Testing
- Apixaban, Warfarin
- Where
- United States
- Sponsor
- Mayo Clinic
Pharmacokinetics, Kidney Transplant
Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients
This study aims to evaluate the pharmacokinetics (PK) of apixaban in kidney and lung transplant recipients stabilized on either cyclosporine or tacrolimus as part of their immunosuppressive therapy.
- Conditions
- Pharmacokinetics, Kidney Transplant, Lung Transplant
- Trial name
- ACT-KLR (NCT04023760)
- Testing
- Apixaban
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University of Saskatchewan